Abstract: Described herein are methods for treating hematological malignancies and/or solid tumors in a subject using inhibitors of integrin alpha 6. In some embodiments, the inhibitors are monoclonal antibodies. The antibodies may be conjugated to additional therapeutic agents. The antibodies may be co-administered sequentially or simultaneously with additional therapeutic agents.

Abstract: The present invention provides methods of modulating cell junctions via the Gp140 membrane protein. Gp140 agonists and antagonists are provided, including activating and non-activating antibodies of Gp140, as well as compositions including the same. Methods of treatment including administration of a Gp140 agonist or antagonist are also provided. Finally, implants having a Gp140 modulator coupled thereto are provided.

Abstract: The present invention relates to a method for inhibiting the adhesion of one cell to another comprising interfering with the interaction between the extracellular matrix receptor and its ligand. The invention is based upon the discovery that the ?4?1 extracellular matrix receptor promotes adhesion of lymphocytes to endothelial cells via attachment to a defined peptide sequence. Prior to the present invention, the ligand of the ?4?1 receptor had not been identified, nor had the function of the ?4?1 receptor in lymphocyte attachment been known. By preventing the interaction between the ?4?1 receptor and its ligands using antibodies or defined peptide sequences, the present invention enables, for the first time, specific intervention in the migration of lymphocytes through the vascular endothelium and into tissues.

Abstract: The present invention relates to a method for inhibiting the adhesion of one cell to another comprising interfering with the interaction between the extracellular matrix receptor and its ligand.

Abstract: The present invention relates to a method for inhibiting the adhesion of one cell to another comprising interfering with the interaction between the extracellular matrix receptor and its ligand.The invention is based upon the discovery that the .alpha.4.beta.1 extracellular matrix receptor promotes adhesion of lymphocytes to endothelial cells via attachment to a defined peptide sequence. Prior to the present invention, the ligand of the .alpha.4.beta.1 receptor had not been identified, nor had the function of the .alpha.4.beta.1 receptor in lymphocyte attachment been known. By preventing the interaction between the .alpha.4.beta.1 receptor and its ligands using antibodies or defined peptide sequences, the present invention enables, for the first time, specific intervention in the migration of lymphocytes through the vascular endothelium and into tissues.